Brought to you by 
Argos closes first tranche of its $35.2mm Series C round
30 Aug 2013
Executive Summary
Argos Therapeutics (immunotherapeutics for cancer and infectious diseases) has closed the first tranche of is Series C round, bringing in over half of the projected $35.2mm. A second closing is expected later this year. TVM Capital led and was joined by new investors Mizuho Capital, Morningside Group, and Japan Asia Investment Co. Existing backers Lumira Capital, Forbion Capital Partners, CDP Capital, Intersouth Partners, Aurora Capital, GeneChem, and Argos's development partner Kirin Pharma also participated.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Argos closes first tranche of its $35.2mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice